论文部分内容阅读
目的观察丹参川芎嗪注射液对肺源性心脏病(肺心病)患者心肺功能的影响。方法将96例肺心病患者随机分为观察组和对照组各48例。对照组给予常规治疗,观察组在对照组治疗的基础上给予丹参川芎嗪注射液治疗,对比2组患者的心肺功能及不良反应。结果治疗前2组左室射血分数(LVEF)、心输出量(CO)及每搏心输出量(SV)水平比较差异均无统计学意义(P>0.05),治疗后2组心功能指标均高于治疗前(P<0.05),且观察组显著高于对照组(P<0.01)。治疗前2组第1秒用力肺活量(FEV1)、用力肺活量(FVC)、最大呼气流速峰值(PEF)及用力呼气量占用力肺活量比值(FEV1/FVC)比较差异无统计学意义(P>0.05),治疗后2组肺功能指标均升高,且观察组明显高于对照组,差异有统计学意义(P<0.01)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论丹参川芎嗪注射液能有效改善肺心病患者的心肺功能,且无明显不良反应,是安全有效的治疗方式。
Objective To observe the effect of ligustrazine injection on cardiorespiratory function in patients with pulmonary heart disease (pulmonary heart disease). Methods 96 cases of pulmonary heart disease were randomly divided into observation group and control group of 48 cases. The control group was given routine treatment. The observation group was given Salviae miltiorrhizae ligustrazine injection on the basis of the control group. The cardiopulmonary function and adverse reactions in the two groups were compared. Results There were no significant differences in LVEF, CO, and SV between the two groups before treatment (P> 0.05). After treatment, 2 groups of cardiac function indexes Were higher than before treatment (P <0.05), and the observation group was significantly higher than the control group (P <0.01). There were no significant differences in FEV1, FVC, PEF and FEV1 / FVC between the two groups before treatment (P> 0.05). After treatment, the indexes of pulmonary function in both groups were increased, and the observation group was significantly higher than the control group (P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Salviae miltiorrhizae ligustrazine injection can effectively improve cardiopulmonary function in patients with pulmonary heart disease, and no obvious adverse reactions, is a safe and effective treatment.